# EDGAR Filing Document

**Accession Number:** 0001129928
**File Stem:** 0001129928-26-000039
**Filing Date:** 2026-6
**Character Count:** 16026
**Document Hash:** 7accf8014e00cd4d9a52e7796a7ec0a0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001129928-26-000039.hdr.sgml**: 20260602

**ACCESSION NUMBER**: 0001129928-26-000039

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260602

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20260602

**DATE AS OF CHANGE**: 20260602

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONCOLYTICS BIOTECH INC
- **CENTRAL INDEX KEY:** 0001129928
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980541667
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38512
- **FILM NUMBER:** 261053818

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 325, 4350 EXECUTIVE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 4036707377

**MAIL ADDRESS:**
- **STREET 1:** SUITE 325, 4350 EXECUTIVE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

?xml version='1.0' encoding='ASCII'? oncy-20260602

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**___________________________________**

**FORM 8-K**

**___________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 2, 2026**

**___________________________________**

**Oncolytics Biotech Inc.**

(Exact name of registrant as specified in its charter)

**___________________________________**

---

| | | | |
|:---|:---|:---|:---|
| **Nevada**<br>(State or other jurisdiction of <br>incorporation) | **001-38512**<br>(Commission File Number) | **001-38512**<br>(Commission File Number) | **98-0541667**<br>(IRS Employer Identification No.) |
| **4350 Executive Drive, Suite 325**<br>**San Diego, CA 92121** | **4350 Executive Drive, Suite 325**<br>**San Diego, CA 92121** | **92121** | **92121** |
| (Address of principal executive offices) | (Address of principal executive offices) | &nbsp;&nbsp;(Zip Code) | &nbsp;&nbsp;(Zip Code) |
| **(403) 670-7377** | **(403) 670-7377** | **(403) 670-7377** | **(403) 670-7377** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |
| **N/A** | **N/A** | **N/A** | **N/A** |
| (Former name or former address, if changed since last report) | (Former name or former address, if changed since last report) | (Former name or former address, if changed since last report) | (Former name or former address, if changed since last report) |

---

**___________________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| <u>Title of each class</u> | <u>Trading Symbol(s)</u> | <u>Name of each exchange on which registered</u> |
| Common stock, par value $0.001 per share | ONCY | The Nasdaq Stock Market LLC |

---

------

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

***Appointment of New Executive Officer***

On June 1, 2026, the Board of Directors (the "Board") of Oncolytics Biotech Inc. (the "Company") appointed John McAdory as Chief Operating Officer of the Company. Mr. McAdory will not receive any additional compensation as a result of the appointment.

Mr. McAdory, age 49, has been appointed Chief Operating Officer of the Company, effective June 1, 2026. Mr. McAdory previously served as Executive Vice President, Strategy and Operations of the Company from January 2026 to June 2026. From January 2020 to January 2026, Mr. McAdory served as Vice President, Clinical Operations at CG Oncology, Inc. (Nasdaq: CGON), where he led clinical operations through its pivotal Phase 3 program and initial public offering. From February 2018 to January 2020, Mr. McAdory served as Head of Clinical Operations at SillaJen, Inc. Earlier in his career, Mr. McAdory held clinical operations positions at UCB and Amgen Inc. Mr. McAdory holds a Master of Health Administration from the University of North Carolina at Chapel Hill and a Bachelor of Science in Biology from Hampton University.

There are no arrangements or understandings between Mr. McAdory and any other persons pursuant to which he was appointed as an officer of the Company. There are no family relationships between Mr. McAdory and any other director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In addition, Mr. McAdory has entered into an indemnification agreement with the Company providing for the indemnification of, and advancement of expenses to, Mr. McAdory in connection with claims, suits, or proceedings arising as a result of his service as a director of the Company.

***Appointment of New Director***

Furthermore, on June 1, 2026, the Board, acting under a unanimous written consent, appointed Stephen Glover as the ninth director of the Board. Mr. Glover will serve as a director of the Company until the next annual meeting of the shareholders or until his successor shall have been elected and qualified subject to his earlier death, resignation, retirement, disqualification or removal.

In connection with his appointment as director, and on June 1, 2026 (the "Grant Date"), the Board granted Mr. Glover an option (the "Option") to purchase 96,000 shares of Company's common stock (the "Stock") with an exercise price equal to the closing price per share of the Stock as reported on Nasdaq on June 1, 2026. The Option is granted pursuant to, and subject to the terms and conditions of, the Oncolytics Biotech Inc. 2026 Incentive Award Plan and standard form of stock option agreement, and shall vest in equal installments of 32,000 shares on the anniversary of the Grant Date for the next three years, subject to Mr. Glover's continued service on the Board on each such vesting date.

Mr. Steve Glover, age 66, has more than 35 years of leadership experience in the biopharmaceutical and life sciences industries. Mr. Glover currently serves as Co-Founder, Chairman, Chief Executive Officer, and President of ZyVersa Therapeutics, which he led to a public listing in December 2022. He also serves as Chairman of the Board of Directors of PDS Biotechnology, a member of the Board of Directors of Biogene Therapeutics, and a board member of the Coulter Foundation at the University of Miami U Innovation Center. Previously, Mr. Glover served as Chairman of the Board of Directors of Ambrx Biopharma, where he helped guide the company through significant growth and its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion. Mr. Glover was also Co-Founder and Chief Business Officer of Coherus BioSciences, Prior to Coherus, he served as President of Insmed Therapeutic Proteins and Executive Vice President and Chief Business Officer of Insmed Incorporated. Earlier in his career, Mr. Glover held leadership positions of increasing responsibility at GSK, Roche, and Amgen. The Board believes that Mr.Glover's extensive experience in executive roles and public company board positions in the pharmaceutical and biotech industries qualifies him to serve as a Board member.

There are no arrangements or understandings between Mr. Glover and any other persons pursuant to which he was appointed as a director of the Company. There are no family relationships between Mr. Glover and any other director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

------

Mr. Glover qualifies as an independent director under the independence requirements set forth under Rule 5605(a)(2) of the Nasdaq Listing Rules and applicable law.

In addition, Mr. Glover has entered into an indemnification agreement with the Company providing for the indemnification of, and advancement of expenses to, Mr. Glover in connection with claims, suits, or proceedings arising as a result of his service as a director of the Company.

The foregoing descriptions of the indemnification agreement do not purport to be complete and are qualified in its entirety by reference to the full text of the form of indemnification and advancement agreement, which is attached as Exhibit 10.15 to the Annual Report on Form 10-K filed on March 30, 2026 and incorporated into this Item 5.02 by reference.

**Item 8.01. Other Events.**

On June 2, 2026, the Company issued a press release announcing the appointments of Stephen Glover to the Board and John McAdory as Chief Operating Officer. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Description</u> |
| 99.1 | <u>[Press Release issued by Oncolytics Biotech Inc., dated as of J](oncybodandcoo.htm)[u](oncybodandcoo.htm)[n](oncybodandcoo.htm)[e](oncybodandcoo.htm)[2](oncybodandcoo.htm)[, 2026](oncybodandcoo.htm)</u>. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 2, 2026

---

| | |
|:---|:---|
| **ONCOLYTICS BIOTECH INC.** | **ONCOLYTICS BIOTECH INC.** |
| By: | /s/ Kirk Look |
| Name: | Kirk Look |
| Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Oncolytics Biotech**<sup>®</sup> **Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer**

**SAN DIEGO, CA, June 2, 2026 –** Oncolytics Biotech<sup>®</sup> Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer ("COO").

Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.

Additionally, Mr. McAdory has been promoted to Chief Operating Officer. As COO, he will oversee the Company's clinical operations and development activities, preclinical research and development efforts, and will play a key role in strategic partnerships and broader business development initiatives. Mr. McAdory joined Oncolytics earlier this year after serving as VP of Clinical Operations at CG Oncology.

"We are thrilled to welcome Steve to our Board at a transformational time for Oncolytics," said Jared Kelly, Chief Executive Officer of Oncolytics. "Steve has extensive experience helping build and position innovative biotechnology companies for strategic growth and value creation, including through the successful sale of Ambrx to Johnson & Johnson. His experience across corporate strategy, financing, and strategic transactions will be invaluable as we continue to advance pelareorep and expand our immunotherapy platform strategy."

Mr. Kelly continued, "I am also very excited to announce John's promotion to Chief Operating Officer. Since joining Oncolytics, John has already had a meaningful impact on our operational execution and clinical development strategy. His background helping advance innovative oncology programs at CG Oncology and his strong operational leadership make him ideally suited to help drive our next phase of growth as we advance our registration-enabling studies, expand our preclinical pipeline, and pursue strategic partnership opportunities."

"I am excited to join the Board of Oncolytics during this important period of clinical and corporate momentum," said Mr. Glover. "I believe pelareorep has the potential to become an important immunotherapy backbone across multiple solid tumor indications, and I look forward to working with the management team and Board to help maximize the platform's value."

"I appreciate the confidence the Board and leadership team have placed in me," said John McAdory, Chief Operating Officer of Oncolytics. "I believe Oncolytics is uniquely positioned with compelling clinical and translational data, particularly in gastrointestinal cancers, and I look forward to helping accelerate and execute on the Company's developmental, operational, and strategic objectives."

**About Oncolytics Biotech Inc.**

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce

------

anti-cancer immune responses by converting immunologically "cold" tumors to "hot" through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.

**Company Contact** 

Jon Patton

Director of IR & Communication

jpatton@oncolytics.com

<br>